Medical Licensing (MD/DO) · Independent exam preparation
ABIM Gastroenterology Certification: Clinical Decisions Guide Study Guide
Study diagnostic interpretation, procedural management, inflammatory disease, hepatology, pancreatic disease, nutrition, and intestinal disorders through 60 focused concepts, 20 clinical questions, and 20 flashcards.
By CertMedbry · Updated 18 October 2026
This selective guide follows the January 2026 blueprint for ABIM's Gastroenterology Certification Examination, applicable beginning with Fall 2026. Its concepts represent all 11 domains in approximate blueprint proportions. Emphasis falls on interpreting clinical findings, selecting appropriate tests, choosing treatment, and recognizing findings that change management.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination does this guide address?
It addresses the American Board of Internal Medicine Gastroenterology Certification Examination. Prior ABIM certification in internal medicine is an eligibility requirement. The workbook label 'ABIM - Subspecialty in Gastroenterology' maps to this physician subspecialty certification examination.
Does Gastroenterology certification include Transplant Hepatology certification?
Transplant Hepatology has a separately named certification examination. Gastroenterology certification precedes eligibility for that pathway. This guide addresses initial Gastroenterology certification; maintenance of certification and the Longitudinal Knowledge Assessment have separate assessment arrangements.
ABIM Gastroenterology Certification Policies · ABIM Expanded Blueprints
Which blueprint applies beginning with Fall 2026?
The January 2026 Gastroenterology certification blueprint explicitly applies beginning with the Fall 2026 certification examination. ABIM's rollout schedule corroborates that date. The expanded outline supplies detailed topics, although its footer refers to MOC and LKA implementation. Establish certification applicability from the certification-specific blueprint and rollout schedule.
Gastroenterology Certification Examination Blueprint — January 2026 · Gastroenterology Certification Examination Expanded Blueprint · ABIM Expanded Blueprints
What are the official domain weights?
Procedures and Periprocedural Issues 13%; Esophageal Disorders 7%; Gastric and Duodenal Disorders 8%; Inflammatory Bowel Disease and Other Immune-Related Disorders 10%; Motility Disorders 5%; Neoplastic Disorders 10%; Liver Disorders 20%; Pancreas and Biliary Tract Disorders 9.5%; Disorders of Gut–Brain Interaction 6%; Nutrition 4%; Other Disorders 7.5%. This guide allocates 8, 4, 5, 6, 3, 6, 12, 6, 3, 2, and 5 concepts respectively. Questions and flashcards each allocate 3, 1, 2, 2, 1, 2, 4, 2, 1, 1, and 1 items.
Gastroenterology Certification Examination Blueprint — January 2026
Which clinical tasks receive the greatest emphasis?
The official targets are Diagnosis/Testing 40%, Treatment/Care Decisions 45%, Risk Assessment/Prognosis/Epidemiology 10%, and Pathophysiology/Basic Science 5%. Health equity spans content areas, including clinically relevant language barriers, low health literacy, food insecurity, and financial barriers affecting care.
Gastroenterology Certification Examination Blueprint — January 2026
What setting and clinical material should candidates expect?
The certification examination is taken in a testing center. Most questions describe patient scenarios and assess physicians' clinical tasks. Clinical information may include photographs, radiographs, CT or MRI images, photomicrographs, pedigrees, tables, and other media. The blueprint directs candidates to ABIM examination tutorials for examples of question format.
Gastroenterology Certification Examination Blueprint — January 2026
How should this selective guide be used with the official outline?
Use these concepts to practise clinical reasoning, then compare your preparation against the complete official outline and expanded blueprint. Representation of every domain does not mean coverage of every disease, procedure, treatment, or task. The 20 clinical questions provide focused practice rather than a complete examination simulation.
Gastroenterology Certification Examination Blueprint — January 2026 · Gastroenterology Certification Examination Expanded Blueprint
The official ABIM outline defines the full examination scope, including substantial material beyond these 60 concepts. These independently authored educational questions and flashcards are not official ABIM items or endorsed materials. Use the complete outline to identify additional study needs.
Outline used: January 2026 Gastroenterology Certification Examination blueprint, applicable beginning with the Fall 2026 certification exam; verified on 2026-10-09. The workbook label 'ABIM - Subspecialty in Gastroenterology' maps to this official examination. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Procedures and Periprocedural Issues13%
1.When should a patient with upper gastrointestinal bleeding receive red cells?
For most hospitalized patients with upper gastrointestinal bleeding, a restrictive red-cell transfusion threshold of hemoglobin 7 g/dL is suggested. Interpret the threshold alongside perfusion, ongoing blood loss, and cardiovascular disease. Acute hemorrhage can initially leave hemoglobin deceptively reassuring because plasma and red cells are lost together. Persistent hypotension can justify transfusion before the measured hemoglobin falls below the usual threshold.
Apply it
A patient with melena has hemoglobin 6.6 g/dL after initial fluids. Arrange transfusion while assessing bleeding severity and preparing definitive evaluation; replacing red cells does not control the lesion.
Common pitfall: Waiting for a laboratory threshold during major ongoing hemorrhage delays resuscitation. Conversely, routinely transfusing a stable patient to a normal hemoglobin adds unnecessary exposure.
2.How do risk assessment and stabilization determine bleeding evaluation?
A Glasgow-Blatchford score of 0–1 identifies a very-low-risk group that may be discharged with reliable outpatient follow-up. Patients admitted or observed for upper gastrointestinal bleeding should generally undergo endoscopy within 24 hours of presentation after initial assessment and resuscitation. The score estimates the risk of intervention or death; it does not identify the bleeding lesion or replace management of shock.
Apply it
Calculate the score before discharging a stable patient with limited melena. For an admitted patient who improves after fluids, arrange endoscopy within 24 hours while continuing clinical reassessment.
Common pitfall: A reassuring appearance does not replace formal risk assessment. Discharge also depends on follow-up access, support, comorbidity, and whether another condition requires admission.
3.How should antithrombotic therapy be managed before elective endoscopy?
Balance procedural bleeding risk against the indication for antithrombotic treatment. Cardiac aspirin used for secondary prevention generally continues. Warfarin can often continue for lower-risk procedures; when interruption is needed for a higher-risk intervention, routine heparin bridging is generally discouraged, with exceptional thrombotic-risk situations requiring individualized assessment. DOACs are generally temporarily interrupted, with timing informed by the agent, renal function, and procedure. See the [ACG–CAG guideline](https://pubmed.ncbi.nlm.nih.gov/35297395/).
Apply it
For planned high-risk polypectomy in a patient taking warfarin for atrial fibrillation without a mechanical valve or recent embolism, assess interruption without automatically adding heparin bridging.
Common pitfall: Stopping every antithrombotic exposes patients to avoidable thrombosis. Recent coronary stenting or very high thrombotic risk may favor deferring an elective intervention rather than applying a routine interruption schedule.
Gastroenterology Certification Examination Expanded Blueprint
4.Which ulcer findings require hemostasis, and what makes treatment durable?
Active spurting, active oozing, and a nonbleeding visible vessel warrant endoscopic treatment. If epinephrine injection is used to slow bleeding and improve visualization, combine it with another hemostatic modality, such as suitable clipping or thermal therapy. After successful treatment of a high-risk ulcer, give high-dose PPI continuously or intermittently for three days, followed by twice-daily oral PPI through two weeks after the index endoscopy.
Apply it
A duodenal ulcer stops bleeding after epinephrine injection. Complete definitive vessel treatment and prescribe the recommended post-hemostasis PPI sequence.
Common pitfall: A visible vessel remains high risk despite hemodynamic stability or absence of active flow. Temporary cessation after epinephrine alone does not establish durable hemostasis.
5.Which findings change sedation and airway planning for endoscopy?
Assess cardiopulmonary disease, prior sedation problems, fasting status, anticipated procedure complexity, and airway anatomy before sedation. Sleep apnea, restricted mouth opening, limited neck movement, and prior difficult airway management can complicate rescue. Deep sedation may impair ventilation and airway protection, so personnel must recognize deterioration and provide rescue from a deeper level than intended. Consider anesthesia support for complex procedures or substantial comorbidity or airway risk. See the [ASGE sedation guideline](https://www.asge.org/home/resources/publications/guidelines/guidelines-for-sedation-and-anesthesia-in-gi-endoscopy).
Apply it
A patient with prior difficult intubation and limited neck extension needs prolonged therapeutic endoscopy. Establish an airway and anesthesia plan before administering sedatives.
Common pitfall: Supplemental oxygen can improve saturation while hypoventilation persists. Monitor ventilation and responsiveness as well as oxygenation; sleep apnea alone does not mandate one sedation technique for every patient.
Gastroenterology Certification Examination Expanded Blueprint
6.What immediate care follows a recognized upper gastrointestinal perforation?
A recognized upper gastrointestinal perforation requires bowel rest, intravenous fluids, broad-spectrum antibiotics covering gram-negative and anaerobic organisms, and surgical consultation. Endoscopic closure may be appropriate when the defect, timing, contamination, and expertise permit. Admission and monitoring remain necessary after technically successful closure because leakage or infection can persist. See the [AGA perforation guidance](https://gastro.org/clinical-guidance/endoscopic-management-of-perforations-in-the-gastrointestinal-tract/).
Apply it
A small perforation is recognized during esophageal dilation and closed endoscopically. Keep the patient NPO, begin supportive and antimicrobial treatment, and obtain surgical review.
Common pitfall: Successful deployment of a closure device does not justify immediate discharge. Hemodynamic instability, delayed recognition with peritoneal signs, or uncontrolled contamination can require surgery.
Gastroenterology Certification Examination Expanded Blueprint
7.What follows recurrent bleeding after initially successful ulcer hemostasis?
Recurrent ulcer hemorrhage generally warrants repeat endoscopy with another attempt at endoscopic treatment. If endoscopic treatment fails, transcatheter arterial embolization is suggested. Resuscitation continues throughout this sequence. Reassessment should distinguish recurrent bleeding from passage of previously shed blood: fresh hematemesis, hemodynamic deterioration, and a falling hemoglobin provide stronger evidence than persistent dark stool alone.
Apply it
After initial clipping, a patient develops fresh hematemesis and hypotension. Resuscitate and arrange repeat therapeutic endoscopy; escalate to embolization if endoscopic control cannot be achieved.
Common pitfall: Persistent melena alone does not prove treatment failure. Conversely, clear recurrent hemorrhage should not be managed solely by increasing acid suppression and waiting for spontaneous improvement.
8.How does teach-back improve procedural counseling?
Teach-back asks patients to explain important instructions in their own words so the clinician can assess whether the explanation was clear and usable. Teach a small amount, check comprehension, clarify misunderstandings, and check again. The method evaluates communication rather than intelligence. It can uncover errors involving preparation timing, medication instructions, transportation, or warning symptoms that a simple statement of agreement would miss.
Apply it
After explaining preparation instructions, ask the patient to describe what they will drink and when. Their explanation reveals a timing error that can be corrected before the procedure.
Common pitfall: Asking whether the patient understands often invites agreement without demonstrating comprehension. Teach-back complements appropriate language assistance and does not replace an interpreter when one is needed.
Esophageal Disorders7%
9.What establishes eosinophilic esophagitis?
Eosinophilic esophagitis requires symptoms of esophageal dysfunction, at least 15 eosinophils per high-power field on esophageal biopsy, and assessment for other causes of esophageal eosinophilia. Recurrent solid-food dysphagia or impaction supplies a characteristic clinical context. Rings and furrows increase suspicion but do not replace histology. A failed PPI trial is no longer required to establish the diagnosis, although a PPI remains a treatment option.
Apply it
An adult with recurrent impactions has qualifying biopsy eosinophilia and no supported alternative explanation. Establish the diagnosis without requiring an unsuccessful course of acid suppression first.
Common pitfall: Neither endoscopic appearance nor eosinophil count should be interpreted in isolation. Peripheral eosinophilia is not required, and an initial response to PPI therapy does not invalidate the diagnosis.
10.How should initial endoscopy and biopsies be prepared for suspected eosinophilic esophagitis?
Obtain at least six targeted biopsies from at least two esophageal levels because inflammation is patchy. Initial diagnostic endoscopy should generally occur off PPI therapy and dietary elimination when clinically appropriate, since these can suppress eosinophilia. Review other potentially suppressive treatments, including inhaled or intranasal corticosteroids, under the prescribing clinician's supervision. Endoscopy assessing treatment response instead evaluates disease during the prescribed treatment. See the [ACG guideline summary](https://gi.org/journals-publications/ebgi/eluri_feb2025/).
Apply it
A negative adequately sampled examination during PPI treatment and food elimination may reflect suppression. Review treatment exposure before treating the result as exclusion of untreated disease.
Common pitfall: Do not stop necessary asthma treatment without supervision. Distinguish avoiding a treatment-related false negative at initial diagnosis from assessing response on therapy; PPI failure is not a diagnostic requirement.
11.When should reflux symptoms prompt empirical treatment or objective testing?
Typical heartburn and regurgitation without alarm features can receive an eight-week trial of once-daily PPI taken before a meal. Dysphagia, gastrointestinal bleeding, or weight loss warrants endoscopic evaluation. Persistent symptoms require checking adherence and administration timing before escalation. When GERD remains unproven after nondiagnostic endoscopy, reflux monitoring off acid suppression can establish abnormal reflux exposure. See the [ACG GERD guideline](https://doi.org/10.14309/AJG.0000000000001538).
Apply it
A patient takes a PPI at bedtime and reports persistent heartburn. Optimize dosing 30–60 minutes before a meal; investigate alarm symptoms rather than attributing them automatically to reflux.
Common pitfall: PPI response alone is not definitive proof of GERD. Reflux monitoring on therapy answers a different question in patients whose GERD has already been objectively established.
Gastroenterology Certification Examination Expanded Blueprint
12.What distinguishes Barrett esophagus from an irregular Z line?
The ACG diagnostic framework requires at least 1 cm of columnar mucosa in the tubular esophagus with intestinal metaplasia. An irregular Z line shorter than 1 cm without a visible lesion should not routinely be biopsied or placed into Barrett surveillance. For established Barrett esophagus, inspect for visible abnormalities and use structured sampling; dysplasia requires confirmation by an expert gastrointestinal pathologist. See the [updated ACG Barrett guideline](https://www.guidelinecentral.com/guideline/1677303/).
Apply it
A 5 mm irregular Z line without a lesion is different from a 3 cm esophageal segment containing intestinal metaplasia. Apply the diagnostic threshold before assigning surveillance.
Common pitfall: Intestinal metaplasia at the gastroesophageal junction does not automatically establish Barrett esophagus. Inflammation can complicate dysplasia interpretation, making expert confirmation consequential.
Gastroenterology Certification Examination Expanded Blueprint
Gastric and Duodenal Disorders8%
13.Which empiric H. pylori regimen avoids assuming clarithromycin susceptibility?
For treatment-naive H. pylori infection with unknown susceptibility, the 2024 ACG recommendations favor optimized bismuth quadruple therapy for 14 days. It combines a PPI, bismuth, tetracycline, and metronidazole. The regimen avoids relying on presumed clarithromycin susceptibility. Review allergies, previous antibiotics, drug availability, and ability to complete the schedule. The highlighted guidance does not recommend substituting doxycycline for tetracycline.
Apply it
A patient with an H. pylori-associated ulcer has no susceptibility results. Select a recommended empiric regimen and explain the complete dosing schedule, including how to obtain all components.
Common pitfall: A familiar clarithromycin regimen may fail when resistance is present. Regimen complexity calls for adherence support rather than omission or casual substitution of necessary components.
ACG Guideline on Treatment of Helicobacter pylori: New Recommendations · ACG-Hpylori-Guidelines-Highlights-2024-FINAL.pdf
14.When is clarithromycin-based H. pylori therapy appropriate?
Avoid empiric PPI-clarithromycin triple therapy unless clarithromycin susceptibility has been demonstrated. Resistance can make the antibiotic ineffective and substantially reduce eradication success. Lack of remembered macrolide exposure does not establish susceptibility. The relevant discriminator is evidence about the organism, rather than convenience, familiarity with the regimen, or successful treatment of a different patient. Prior antibiotic exposure remains useful context when selecting treatment.
Apply it
One patient has documented clarithromycin-susceptible infection; another has no susceptibility information. The result can support considering clarithromycin treatment for the first patient without justifying the same empirical choice for the second.
Common pitfall: A remote personal treatment success or presumed regional susceptibility does not establish the current organism's susceptibility. Symptoms after treatment also cannot determine whether resistance caused treatment failure.
ACG Guideline on Treatment of Helicobacter pylori: New Recommendations · ACG-Hpylori-Guidelines-Highlights-2024-FINAL.pdf
15.How should H. pylori eradication be confirmed?
Confirm eradication in all treated patients using a urea breath test, fecal antigen test, or appropriate biopsy-based testing. Test at least four weeks after treatment, withholding antibiotics and bismuth for at least four weeks and PPIs or potassium-competitive acid blockers for at least two weeks. These treatments can suppress detection and produce false-negative results. Antibody testing does not reliably distinguish prior exposure from persistent infection after treatment.
Apply it
A patient feels well after therapy but continues bismuth and a PPI. Arrange confirmation after the relevant medication washouts rather than accepting an immediate negative test as proof of cure.
Common pitfall: Symptom resolution does not establish eradication. Remember the bismuth washout as well as antibiotic and acid-suppression timing when interpreting a negative result.
ACG Guideline on Treatment of Helicobacter pylori: New Recommendations · ACG-Hpylori-Guidelines-Highlights-2024-FINAL.pdf
16.Why can autoimmune gastritis cause both iron and vitamin B12 deficiency?
Autoimmune gastritis damages gastric functions needed for nutrient absorption. Reduced acid can impair iron absorption, while inadequate intrinsic factor impairs vitamin B12 absorption in the terminal ileum. Iron deficiency and B12 deficiency can therefore be connected consequences rather than unrelated dietary problems. Coexisting deficiencies may obscure the expected red-cell size pattern. Assess the clinical findings and relevant nutrient measures rather than using mean corpuscular volume as the only gatekeeper.
Apply it
A patient with autoimmune gastritis has low ferritin, fatigue, and distal tingling despite eating animal products. Assess B12 as well as iron rather than assuming one deficiency explains the entire presentation.
Common pitfall: Adequate intake does not exclude malabsorption. A normal mean corpuscular volume also cannot reliably exclude important B12 deficiency, especially when another deficiency changes the hematologic pattern.
NIDDK: Eating, Diet, and Nutrition for Gastritis and Gastropathy · NIH Office of Dietary Supplements: Vitamin B12
17.How should gastric outlet obstruction be distinguished from a gastric motor disorder?
Gastric outlet obstruction is a structural impediment to passage through the distal stomach or duodenum. Persistent vomiting, early satiety, and weight loss require evaluation for an obstructing lesion before assigning gastroparesis. Endoscopy and cross-sectional imaging help define the narrowing and its cause; evaluate for malignancy as well as peptic stenosis. Treatment depends on etiology, anatomy, and patient fitness. See the [ASGE gastroduodenal obstruction guideline](https://www.asge.org/home/resources/publications/guidelines/asge-guideline-on-the-role-of-endoscopy-in-the-management-of-benign-and-malignant-gastroduodenal-obstruction).
Apply it
A patient with progressive vomiting and weight loss has a fixed pyloric narrowing. Assess the cause and obtain appropriate tissue rather than ordering an emptying study as the first definitive assessment.
Common pitfall: Retained gastric contents occur with both obstruction and delayed emptying. A history of ulcer disease does not establish that a new narrowing is benign.
Gastroenterology Certification Examination Expanded Blueprint
Inflammatory Bowel Disease and Other Immune-Related Disorders10%
18.What evaluation accompanies hospitalization for acute severe ulcerative colitis?
Acute severe ulcerative colitis requires testing for Clostridioides difficile, assessment for toxic megacolon, and early flexible sigmoidoscopy, within 72 hours and preferably within 24 hours. Obtain biopsies to assess for cytomegalovirus colitis. Intravenous corticosteroids provide initial anti-inflammatory treatment, and pharmacologic venous thromboembolism prophylaxis is recommended. Follow stool frequency, rectal bleeding, vital signs, examination, and inflammatory markers to identify response or deterioration.
Apply it
A hospitalized patient with frequent bloody stools and systemic illness needs infection testing and a limited endoscopic assessment alongside treatment. Arrange serial reassessment rather than making the admission plan a one-time decision.
Common pitfall: CMV assessment should not be forgotten during sigmoidoscopy. Bloody diarrhea alone does not eliminate the recommendation for pharmacologic thromboprophylaxis in hospitalized acute severe colitis.
The Updated 2025 ACG Guidelines to Manage Adult Ulcerative Colitis Patients
19.When should acute severe ulcerative colitis trigger rescue therapy?
Assess response to intravenous corticosteroids early in acute severe ulcerative colitis. Inadequate improvement by approximately day three warrants consideration of infliximab or cyclosporine rescue therapy. Involve surgery early because medication failure or urgent complications may require colectomy. A defined reassessment point limits exposure to ineffective steroids and helps prevent delayed definitive treatment. Rescue therapy is an opportunity to control disease, not a guarantee that surgery can be avoided.
Apply it
After three days of intravenous corticosteroids, a patient continues frequent bloody stools and substantial inflammatory activity. Discuss rescue selection and surgical planning rather than extending steroid monotherapy without a clear endpoint.
Common pitfall: Perforation, uncontrolled hemorrhage, toxic megacolon, or deterioration can require urgent surgery. Such findings override a predetermined plan to complete additional days of medication.
The Updated 2025 ACG Guidelines to Manage Adult Ulcerative Colitis Patients
20.How should suspected Crohn disease be characterized before treatment?
Establish Crohn disease by integrating clinical findings with endoscopic, histologic, and radiologic evidence. Ileocolonoscopy with biopsies assesses mucosal distribution, while small-bowel imaging assesses disease beyond endoscopic reach and complications. Define location and inflammatory, stricturing, or penetrating behavior because symptoms alone cannot distinguish them. Fecal calprotectin supports assessment of intestinal inflammation but is not disease-specific. See the [BSG IBD guideline](https://gut.bmj.com/content/74/Suppl_2/s1) and [ACG Crohn guidance](https://mediacdn.gi.org/giorgcdn/wp-content/uploads/2018/04/ACG_CrohnsHighight2025.pdf).
Apply it
A patient has chronic diarrhea, weight loss, and terminal ileal ulceration. Obtain biopsies and assess the remaining small bowel rather than assuming colonoscopy describes the entire disease burden.
Common pitfall: Elevated calprotectin does not independently diagnose Crohn disease. Obstructive symptoms require assessment for stenosis rather than automatic escalation of anti-inflammatory treatment.
Gastroenterology Certification Examination Expanded Blueprint
21.How do abscesses and fixed strictures change Crohn disease management?
An intra-abdominal abscess requires infection control with antibiotics and drainage when feasible; ACG guidance specifically recommends drainage and antibiotics for abscesses larger than 2 cm. Do not substitute corticosteroid escalation for source control. Symptomatic fibrostenotic strictures and abscesses warrant surgical assessment. After stabilization, choose medical and surgical strategies together. Corticosteroids may induce improvement in inflammatory disease but are unsuitable for maintenance. See the [ACG Crohn guidance](https://mediacdn.gi.org/giorgcdn/wp-content/uploads/2018/04/ACG_CrohnsHighight2025.pdf).
Apply it
A patient with Crohn disease has fever and a 4 cm intra-abdominal abscess. Arrange antibiotics, drainage, and surgical involvement before pursuing escalation of immunosuppression.
Common pitfall: Pain in established Crohn disease does not necessarily represent an uncomplicated inflammatory flare. Fixed fibrosis will not reliably resolve with stronger immunosuppression.
Gastroenterology Certification Examination Expanded Blueprint
22.How should IgA status guide celiac serology?
Tissue transglutaminase IgA is a useful celiac test when the patient is consuming gluten and has adequate IgA. Marked IgA deficiency makes a negative IgA-based result unreliable. Use appropriate IgG-based tests, such as tissue transglutaminase IgG or deamidated gliadin peptide IgG, when IgA is deficient. The assay must match the patient's immunoglobulin status; simply repeating the same deficient antibody class does not solve the problem.
Apply it
A patient eating gluten has iron deficiency, negative tissue transglutaminase IgA, and markedly low total IgA. Obtain suitable IgG-based testing rather than declaring celiac disease excluded.
Common pitfall: Isolated IgG testing can be misleading when IgA is normal. Interpret test selection in context instead of treating all antibody assays as interchangeable measures.
23.How do gluten exposure and biopsy distribution affect celiac diagnosis?
Perform celiac testing while the patient is eating gluten because avoidance can reduce antibodies and allow mucosal healing. Adult confirmation commonly includes duodenal biopsies from both the bulb and distal duodenum because injury may be patchy. A negative serologic result requires interpretation of gluten exposure and immunoglobulin status. Strong clinical suspicion can justify further evaluation despite negative antibodies when those limitations or other supporting findings are present.
Apply it
An adult with positive celiac serology undergoes endoscopy. Sample both the duodenal bulb and distal duodenum rather than taking a single specimen from one normal-looking location.
Common pitfall: Symptom improvement after avoiding wheat does not establish celiac disease. Starting a strict gluten-free diet before completing evaluation can make both serology and histology less informative.
Motility Disorders5%
24.What establishes gastroparesis, and how can diet support treatment?
Gastroparesis requires compatible symptoms, objectively delayed gastric emptying, and exclusion of mechanical obstruction. Standardized solid-meal scintigraphy through four hours supplies objective evidence. Diabetes, vomiting, or retained food at endoscopy cannot independently establish the diagnosis. A small-particle diet can improve tolerance by reducing the processing needed before food leaves the stomach, but dietary changes must preserve adequate calories and nutrients.
Apply it
A patient with diabetes and vomiting has no obstruction. Obtain properly prepared solid-meal testing; if delayed emptying is confirmed, adapt food texture while monitoring intake and weight.
Common pitfall: A shortened or liquid-only study does not provide the same assessment. Progressive food avoidance can worsen malnutrition even when it reduces symptoms.
ACG Clinical Guideline on Gastroparesis: Limited Evidence-Based Options
25.How should medications and glucose be managed before gastric emptying testing?
Relevant motility-altering medicines are usually withheld for approximately 48 hours before testing, individualized to pharmacokinetics, clinical necessity, and the laboratory protocol. Review opioids, cannabinoids, prokinetics, and other agents that can affect emptying. Assess glucose before testing and control substantial hyperglycemia because acute hyperglycemia itself delays gastric emptying. Document unavoidable medication or glycemic confounders. See the [ACG gastroparesis guideline](https://pmc.ncbi.nlm.nih.gov/articles/9373497/) and its [testing preparation recommendations](https://gi.org/guideline/management-of-gastroparesis/).
Apply it
A patient arrives after taking a prokinetic and has marked hyperglycemia. Coordinate correction and appropriate testing conditions rather than treating the result as an unconfounded measurement.
Common pitfall: Forty-eight hours is a usual preparation interval, not an adequate washout for every agent. Delayed emptying during marked hyperglycemia or opioid exposure may overstate intrinsic motor dysfunction.
ACG Clinical Guideline on Gastroparesis: Limited Evidence-Based Options
26.How is achalasia distinguished from structural dysphagia?
Achalasia combines impaired lower esophageal sphincter relaxation with absent normal peristalsis. Dysphagia to both solids and liquids, regurgitation, and esophageal retention suggest a motor disorder. Endoscopy excludes an obstructing lesion or pseudoachalasia; high-resolution manometry establishes and subtypes the motor abnormality. Timed barium esophagram complements assessment of emptying. See the [ACG achalasia guideline](https://gi.org/guideline/diagnosis-and-management-of-achalasia/).
Apply it
A patient has progressive solid and liquid dysphagia without a mucosal obstruction. Proceed to high-resolution manometry rather than repeatedly treating presumed reflux.
Common pitfall: A normal-looking esophagus does not exclude achalasia. Rapid weight loss, older age, or difficulty traversing the junction should raise concern for malignant pseudoachalasia even when the initial mucosal examination is unrevealing.
Gastroenterology Certification Examination Expanded Blueprint
Neoplastic Disorders10%
27.How do phenotype and inheritance distinguish major colorectal cancer syndromes?
Lynch syndrome involves inherited mismatch-repair dysfunction and can present with colorectal or extracolonic cancer without extensive polyposis. Classic APC-associated familial adenomatous polyposis produces numerous adenomas and usually follows autosomal dominant inheritance. MUTYH-associated polyposis generally requires biallelic pathogenic variants and follows autosomal recessive inheritance. Adenoma burden, age, associated cancers, and pedigree direct evaluation, but the phenotype does not replace appropriate molecular confirmation.
Apply it
Early colorectal cancer with few adenomas suggests a different pathway from hundreds of adenomas. Polyposis among siblings without a vertical pedigree raises consideration of recessive disease.
Common pitfall: A sparse family history does not exclude inherited susceptibility. One MUTYH variant is not equivalent to confirmed biallelic MUTYH-associated polyposis, and adenoma count alone does not identify every syndrome.
28.Which malignant colorectal polyp findings make endoscopic removal alone insufficiently reassuring?
For a nonpedunculated malignant polyp, high-risk findings include poor differentiation, lymphovascular invasion, submucosal invasion deeper than 1 mm, tumor at the cautery margin, or tumor budding. Assess en bloc removal and whether pathology can reliably evaluate depth and margins. These findings prompt discussion of oncologic resection with lymph-node assessment, balanced against surgical risk and patient preferences. See the [US Multi-Society Task Force recommendations](https://www.asge.org/home/resources/publications/guidelines/endoscopic-recognition).
Apply it
A completely removed nonpedunculated lesion contains submucosally invasive cancer with lymphovascular invasion. Arrange surgical evaluation rather than assuming visual clearance established cure.
Common pitfall: An apparently clear resection site cannot exclude nodal disease. Pedunculated lesions have different margin criteria; morphology matters when applying risk rules.
Gastroenterology Certification Examination Expanded Blueprint
29.How does MLH1 promoter methylation refine hereditary cancer assessment?
MLH1 promoter hypermethylation can silence MLH1 and provide a common sporadic explanation for colorectal tumor loss of MLH1 and PMS2. Appropriate methylation and BRAF testing help distinguish mechanisms after an abnormal tumor screen. The finding explains deficient mismatch repair rather than restoring normal function. It also differs from demonstrating a germline pathogenic variant, which requires a separate interpretive and testing pathway.
Apply it
An older patient's MLH1/PMS2-deficient tumor has MLH1 promoter methylation. Explain the supported sporadic mechanism while checking whether unusually young age or a strong pedigree warrants additional hereditary assessment.
Common pitfall: Abnormal staining alone does not establish Lynch syndrome. Conversely, a tumor result should not be used mechanically to dismiss compelling hereditary features elsewhere in the clinical history.
30.How should confirmed Barrett high-grade dysplasia with a visible lesion be treated?
Confirm dysplasia through expert pathology review. In an appropriate candidate with Barrett high-grade dysplasia or intramucosal cancer, endoscopic eradication therapy is recommended. Resect visible lesions before ablating the remaining Barrett mucosa because resection establishes depth, differentiation, and margin information that biopsies alone may miss. Deeper invasion or adverse pathology changes the oncologic plan. See the [updated ACG Barrett guideline](https://www.guidelinecentral.com/guideline/1677303/).
Apply it
A nodular Barrett segment has confirmed high-grade dysplasia. Arrange expert endoscopic resection of the nodule before selecting ablation for residual flat Barrett mucosa.
Common pitfall: Ablating a visible lesion first destroys tissue needed for staging. Eradication therapy also requires subsequent surveillance because recurrent metaplasia or neoplasia can occur.
Gastroenterology Certification Examination Expanded Blueprint
31.When can a small liver observation meet LR-5 criteria?
CT/MRI LI-RADS applies to defined populations at risk for hepatocellular carcinoma. Under diagnostic v2018 criteria, a 10–19 mm observation with nonrim arterial-phase hyperenhancement and nonperipheral washout meets LR-5. Eligibility, adequate multiphasic technique, size, and enhancement pattern all matter. Rim enhancement and targetoid features indicate a different diagnostic pathway. Ancillary features alone cannot upgrade an observation to LR-5.
Apply it
A patient with cirrhosis has a 15 mm observation with nonrim arterial enhancement and nonperipheral washout. Recognize LR-5 rather than assigning a lower category simply because the lesion is smaller than 2 cm.
Common pitfall: Applying LI-RADS to an ineligible low-risk patient overstates certainty. Peripheral washout and rim enhancement cannot substitute for the specified major features.
ACR LI-RADS CT/MRI v2018 Core · ACR Liver Imaging Reporting and Data System
32.Which patients with MASLD warrant routine hepatocellular carcinoma surveillance?
Cirrhosis is a major boundary for routine hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease. AASLD supports surveillance in eligible patients with cirrhosis but does not recommend routine surveillance for everyone with noncirrhotic MASLD. HCC can occur without cirrhosis, yet that possibility does not establish a favorable surveillance strategy for the entire noncirrhotic population. Fibrosis stage and the possibility of meaningful cancer treatment remain central.
Apply it
Compare two patients with MASLD: one has established cirrhosis and the other has uncomplicated steatosis. The cirrhotic patient fits the routine surveillance pathway rather than both qualifying solely through MASLD.
Common pitfall: Normal aminotransferases do not remove established cirrhotic cancer risk. Reports of noncirrhotic HCC also do not justify universal surveillance of every patient with steatosis.
AASLD: HCC in Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Disorders20%
33.Why is prompt paracentesis important when a patient with cirrhosis is hospitalized?
Hospitalized patients with cirrhosis and ascites need prompt diagnostic paracentesis because spontaneous bacterial peritonitis can be clinically subtle. Confusion or worsening kidney function may be the presenting clue even without fever or abdominal tenderness. Fluid cell count and differential directly assess the neutrophilic response, while cultures help characterize infection. Waiting for classic peritoneal symptoms can delay recognition of a treatable precipitant of decompensation.
Apply it
A patient with ascites develops new confusion and rising creatinine. Arrange diagnostic paracentesis promptly rather than attributing both findings automatically to progression of liver disease.
Common pitfall: Absence of fever does not exclude infection. A prior reassuring paracentesis also cannot establish that a new episode of deterioration has the same cause or remains uninfected.
AASLD: Why Timing Matters — Paracentesis on Admission for Cirrhosis with Ascites
34.Which ascitic cell count meets the treatment threshold for spontaneous bacterial peritonitis?
An ascitic polymorphonuclear neutrophil count of at least 250 cells/mm3 meets the treatment threshold for spontaneous bacterial peritonitis in the appropriate setting. Multiply total nucleated cells by the neutrophil fraction to obtain the absolute count. Culture positivity is not required before treating qualifying neutrocytic ascites. Also assess whether the presentation suggests secondary peritonitis from a surgically treatable source rather than assuming every infected fluid collection is spontaneous.
Apply it
Fluid contains 800 nucleated cells/mm3 with 40% neutrophils. The absolute count is 320 cells/mm3, exceeding the threshold even while cultures remain pending.
Common pitfall: The threshold applies to neutrophils rather than total cells. Negative cultures and lack of fever do not negate a qualifying neutrophil count.
AASLD: Why Timing Matters — Paracentesis on Admission for Cirrhosis with Ascites
35.How should the serum-ascites albumin gradient be calculated?
Calculate the serum-ascites albumin gradient by subtracting ascitic albumin from serum albumin using contemporaneous samples. A gradient of at least 1.1 g/dL supports portal hypertension as the mechanism of ascites. The gradient describes pressure-related physiology rather than proving cirrhosis. Interpret it with total ascitic protein, examination findings, and the broader clinical setting to determine which portal hypertensive process is most plausible.
Apply it
Serum albumin is 3.0 g/dL and ascitic albumin is 1.2 g/dL. The gradient is 1.8 g/dL, supporting portal hypertension and prompting further interpretation of the cause.
Common pitfall: Reversing the subtraction produces an erroneous result. Ascitic total protein is a separate measurement and should not be substituted for ascitic albumin in the calculation.
AASLD: Why Timing Matters — Paracentesis on Admission for Cirrhosis with Ascites
36.How does ascitic protein refine a high albumin gradient?
Among fluids with a serum-ascites albumin gradient of at least 1.1 g/dL, total protein helps refine the mechanism. Protein below 2.5 g/dL commonly fits cirrhotic ascites, while protein at least 2.5 g/dL suggests cardiac congestion in the appropriate context. Neither measurement should be interpreted alone. Elevated jugular venous pressure and other evidence of congestion strengthen the cardiac interpretation of high-gradient, high-protein fluid.
Apply it
A patient has a gradient of 1.7 g/dL, ascitic protein 3.1 g/dL, and elevated jugular venous pressure. Investigate a cardiac contribution instead of declaring cirrhosis from the gradient alone.
Common pitfall: High protein does not exclude portal hypertension. The gradient establishes one physiologic distinction, while protein and clinical findings help explain the process producing it.
AASLD: Why Timing Matters — Paracentesis on Admission for Cirrhosis with Ascites
37.Why is hepatic encephalopathy a clinical diagnosis?
Hepatic encephalopathy is diagnosed from the presentation, underlying liver disease or portosystemic shunting, and evaluation for competing causes of altered mental status. An elevated ammonia value alone does not establish the diagnosis or reliably grade its severity. Clinical examination and the course after treatment are more useful than repeatedly chasing a laboratory value. A normal ammonia result should prompt reconsideration of the proposed diagnosis.
Apply it
A patient with cirrhosis is confused and has an elevated ammonia level. Evaluate medications, infection, bleeding, metabolic disturbances, and other causes while considering encephalopathy rather than stopping the assessment at the laboratory result.
Common pitfall: Cirrhosis does not make every episode of confusion hepatic encephalopathy. Serial ammonia measurements cannot substitute for following orientation, function, examination findings, and the underlying trigger.
38.How should lactulose and precipitant management be combined?
Lactulose is a first-line treatment for overt hepatic encephalopathy and is commonly titrated to about two to three soft bowel movements daily. Concurrently seek infection, gastrointestinal bleeding, constipation, dehydration, electrolyte disturbances, and sedating medicines. These triggers require correction because intestinal nitrogen treatment alone may not resolve the episode. Excess catharsis can itself cause dehydration and electrolyte abnormalities, increasing recurrence risk.
Apply it
A patient becomes oriented but develops eight watery stools daily and orthostasis. Assess hydration and electrolytes and reduce excessive catharsis rather than increasing lactulose because ammonia remains elevated.
Common pitfall: More bowel movements are not always better. Starting lactulose does not complete the investigation, and normalization of ammonia is not the treatment target.
39.How should FIB-4 guide fibrosis triage across age groups?
FIB-4 combines age, AST, ALT, and platelets to estimate advanced-fibrosis risk. In many adults with MASLD, a result below 1.3 supports a lower-risk pathway, while a result at or above 1.3 prompts secondary assessment such as vibration-controlled transient elastography. Use a threshold of 2.0 in adults older than 65 and recognize reduced accuracy below age 35. Acute illness can distort the inputs. FIB-4 triages risk rather than independently diagnosing cirrhosis.
Apply it
A middle-aged patient has FIB-4 1.8 during stable health. Obtain secondary fibrosis assessment. Interpret a similar result differently in an older adult or during acute illness.
Common pitfall: Normal aminotransferases do not exclude advanced fibrosis. A low score in a young patient with concerning features should not automatically end assessment.
40.Which findings identify acute liver failure and require urgent transplant-center involvement?
Acute liver failure generally combines acute liver injury developing within 26 weeks, INR at least 1.5, and hepatic encephalopathy in a patient without preexisting cirrhosis. It requires urgent critical care and early transplant-center involvement because deterioration can be rapid. Investigate acetaminophen exposure, other drugs and supplements, viral hepatitis, autoimmune disease, and vascular causes while providing cause-specific treatment. See the [AASLD acute liver failure position paper](https://www.aasld.org/sites/default/files/2022-07/AcuteLiverFailureUpdate201journalformat1.pdf).
Apply it
A previously healthy adult with acute jaundice develops confusion and INR 2.3. Arrange urgent transfer discussions while evaluating the cause rather than waiting for a prognostic threshold for listing.
Common pitfall: Marked aminotransferase elevation alone is acute injury, not necessarily failure. Conversely, falling aminotransferases do not establish recovery if INR, mental status, lactate, or organ function worsen.
Gastroenterology Certification Examination Expanded Blueprint
41.How do hepatitis B markers distinguish infection, vaccination, and prior natural exposure?
Positive HBsAg, total anti-HBc, and IgM anti-HBc support acute infection in the appropriate setting, although IgM can also appear during severe chronic flares. Negative HBsAg with positive anti-HBs and negative total anti-HBc supports vaccine-induced immunity. Resolved natural infection generally leaves both anti-HBs and total anti-HBc. Vaccination does not generate core antibody; prior natural exposure has implications for reactivation during immunosuppression.
Apply it
Before immunosuppression, negative HBsAg with positive anti-HBs and total anti-HBc indicates prior natural infection rather than vaccination alone.
Common pitfall: HBsAg alone cannot distinguish acute from chronic infection. Anti-HBs alone cannot identify the source of immunity, and isolated core antibody requires a separate contextual assessment.
42.When should decompensated cirrhosis prompt liver transplant evaluation?
Clinically significant ascites and related complications should prompt consideration of referral for liver transplant evaluation. Referral allows assessment of expected benefit, comorbidity, frailty, nutrition, psychosocial needs, and potentially reversible barriers while complications are actively managed. Evaluation does not itself establish listing eligibility or require stopping disease-directed care. See the [AASLD ascites guidance](https://www.aasld.org/practice-guidelines/diagnosis-evaluation-and-management-ascites-spontaneous-bacterial-peritonitis).
Apply it
A patient develops clinically significant ascites despite a previously compensated course. Begin transplant evaluation discussions alongside ascites treatment rather than waiting for repeated critical-care admissions.
Common pitfall: Temporary improvement after paracentesis does not reverse the prognostic significance of decompensation. A numerical severity score should be integrated with complications and candidacy assessment.
Gastroenterology Certification Examination Expanded Blueprint
43.Why does a reactive hepatitis C antibody require RNA testing?
Hepatitis C antibody indicates exposure but does not distinguish current infection from spontaneously cleared or successfully treated infection. Detectable HCV RNA establishes current infection. Reactive antibody with undetectable RNA generally means no current infection, although recent exposure or other special circumstances may warrant repeat RNA testing. After prior clearance, suspected reinfection is assessed with RNA because antibodies commonly remain detectable.
Apply it
A previously treated patient has reactive antibody during screening. Obtain HCV RNA instead of assuming treatment failure or repeating antibody testing to demonstrate clearance.
Common pitfall: Positive antibody is not proof of active viremia. Negative antibody can also miss very recent infection before seroconversion, so exposure timing can change the appropriate test.
44.What treatment begins before endoscopy for suspected acute variceal hemorrhage?
In suspected variceal hemorrhage, begin vasoactive therapy such as octreotide and short-course antibiotic prophylaxis while resuscitating and arranging endoscopy. Endoscopy should generally occur within 12 hours after initial stabilization; esophageal varices are treated with band ligation. Selected high-risk patients need assessment for early TIPS rather than waiting for recurrent hemorrhage. See the [AASLD variceal bleeding review](https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-we-use-early-tips-management-variceal-bleeding).
Apply it
A patient with cirrhosis presents with hematemesis. Start vasoactive treatment and antibiotics during stabilization rather than waiting for endoscopic confirmation.
Common pitfall: PPI therapy alone does not address portal-pressure-driven hemorrhage. Antibiotics serve an established prophylactic role in this setting even when an infection has not yet been demonstrated.
Gastroenterology Certification Examination Expanded Blueprint
Pancreas and Biliary Tract Disorders9.5%
45.How are acute pancreatitis diagnosis and early imaging decisions linked?
Acute pancreatitis generally requires two of three findings: characteristic abdominal pain, pancreatic enzymes more than three times the upper limit of normal, or compatible imaging. When characteristic pain and enzyme elevation already establish the diagnosis, immediate CT is unnecessary solely to obtain a third criterion. Imaging is useful when diagnosis is uncertain or complications require assessment. Clinical severity must be evaluated separately from whether the diagnostic criteria are met.
Apply it
A patient has characteristic pain and lipase six times normal. Begin appropriate care without requiring immediate CT merely to confirm findings that already satisfy the diagnostic framework.
Common pitfall: The magnitude of lipase elevation does not by itself determine severity. A diagnostic imaging decision should answer a clinical question rather than serve as an automatic response to an elevated enzyme.
46.How is chronic pancreatitis assessed when pancreatic enzymes are unrevealing?
Chronic pancreatitis is a fibroinflammatory disorder with irreversible structural damage and possible exocrine or endocrine failure. CT or MRI is recommended for first-line diagnosis; EUS can help when uncertainty persists after cross-sectional imaging. Evaluate pain, nutritional status, alcohol and tobacco exposure, and complications. Structural assessment and pancreatic function assessment answer related but different questions. See the [ACG chronic pancreatitis guideline](https://doi.org/10.14309/ajg.0000000000000535).
Apply it
A patient with recurrent pancreatic-type pain and weight loss has normal lipase. Assess pancreatic structure and function rather than using the enzyme result to exclude chronic disease.
Common pitfall: An acute-pancreatitis enzyme threshold is not a diagnostic requirement for chronic pancreatitis. New focal abnormalities or progressive weight loss also require assessment for pancreatic malignancy.
Gastroenterology Certification Examination Expanded Blueprint
47.How should exocrine pancreatic insufficiency be diagnosed and treated?
Suspect exocrine pancreatic insufficiency with steatorrhea, weight loss, or fat-soluble vitamin deficiency in a high-risk setting such as chronic pancreatitis. Measure fecal elastase on semisolid or solid stool: below 100 micrograms/g strongly supports insufficiency; 100–200 is indeterminate. Once diagnosed, prescribe pancreatic enzymes during meals and snacks and monitor nutritional response. Symptom response to an enzyme trial is not a reliable diagnostic test. See the [AGA practice update](https://pubmed.ncbi.nlm.nih.gov/37737818/).
Apply it
A patient with chronic pancreatitis has weight loss and fecal elastase 70 micrograms/g on formed stool. Begin enzyme replacement with food and assess weight and vitamin status.
Common pitfall: A watery specimen can dilute fecal elastase. Pancreatic imaging identifies structural disease but does not independently establish exocrine insufficiency.
Gastroenterology Certification Examination Expanded Blueprint
48.When does biliary pancreatitis require early ERCP?
Acute pancreatitis complicated by cholangitis warrants early ERCP, generally within 24 hours, because infected biliary obstruction requires drainage. Biliary pancreatitis without cholangitis does not automatically require early ERCP. If a retained common bile duct stone is suspected without an immediate therapeutic indication, EUS or MRCP can clarify the ductal findings. The decisive issue is a therapeutic drainage need rather than the presence of pancreatitis alone.
Apply it
A patient with gallstone pancreatitis develops fever, jaundice, and an obstructed duct. Arrange therapeutic ERCP for associated cholangitis rather than waiting for pancreatic inflammation to settle.
Common pitfall: ERCP is not a routine diagnostic procedure for every gallstone pancreatitis episode. Conversely, temporary hemodynamic improvement does not remove the source-control indication in established cholangitis.
49.Why are prophylactic antibiotics inappropriate for sterile pancreatic necrosis?
Pancreatic inflammation and necrosis do not themselves establish bacterial infection. The ACG guidance advises against prophylactic antibiotics for sterile necrosis. Use antibiotics for established or strongly suspected infection, including relevant extrapancreatic infections. Fever and inflammatory markers require interpretation because sterile pancreatitis can produce systemic inflammation. A CT description of necrosis should prompt appropriate clinical monitoring without automatically being translated into an antibiotic indication.
Apply it
A stable patient has pancreatic necrosis without evidence of infection. Continue appropriate supportive care and reassessment rather than prescribing antibiotics solely to prevent a future infection.
Common pitfall: Necrosis is not synonymous with infection. The converse error is also dangerous: new sepsis or deterioration should not be dismissed automatically as an expected sterile inflammatory response.
50.When should cholecystectomy follow mild gallstone pancreatitis?
A suitable surgical candidate recovering from mild biliary pancreatitis should generally undergo cholecystectomy during the same admission, preferably before discharge, to reduce recurrent biliary events. This recommendation should not be transferred indiscriminately to necrotizing or otherwise complicated pancreatitis, where collections and instability may change timing. Treatment of a duct stone addresses the ductal event without necessarily removing the gallbladder source of future stones.
Apply it
A patient tolerates food after mild gallstone pancreatitis and has no necrosis or collections. Arrange cholecystectomy before discharge rather than leaving an unspecified future operation.
Common pitfall: Successful ERCP does not automatically replace gallbladder management in a fit candidate. Residual lipase elevation alone should not dictate an unnecessary delay after clinical recovery.
Disorders of Gut–Brain Interaction6%
51.How should a low-FODMAP trial be used for irritable bowel syndrome?
A low-FODMAP approach temporarily reduces fermentable carbohydrates that can increase intestinal water and gas, potentially improving IBS symptoms. Follow a limited restriction period with gradual reintroduction to identify individual triggers. The long-term objective is the broadest tolerable diet, with adequate nutrition, rather than permanent exclusion of every food removed initially. Nutrition support is especially helpful when baseline intake is already narrow.
Apply it
A patient improves during the initial trial but fears all excluded foods. Plan systematic reintroduction so tolerated choices can return and the diet becomes more sustainable.
Common pitfall: Improvement does not diagnose food allergy or prove that every excluded food is harmful. Indefinite broad restriction can impair dietary adequacy without adding symptom benefit.
NIDDK: Eating, Diet, and Nutrition for Irritable Bowel Syndrome
52.Why can psychological therapies improve irritable bowel syndrome symptoms?
IBS involves interactions among bowel function, symptom perception, and brain processing. Cognitive behavioral therapy and gut-directed hypnotherapy can modify responses to gastrointestinal symptoms and reduce their impact. These therapies address a relevant gut–brain pathway and do not require a psychiatric diagnosis to be considered. They can complement dietary and bowel-pattern-directed treatment according to patient preferences, symptom burden, and access.
Apply it
A patient has persistent IBS pain and anticipatory anxiety despite reasonable bowel-directed care. Explain gut-directed therapy as active symptom treatment and describe how it fits alongside the existing plan.
Common pitfall: Describing symptoms as imaginary undermines understanding and trust. Equally, the availability of psychological therapy should not prevent reassessment when the clinical pattern changes or new concerning findings appear.
53.Which type of fiber is useful for many patients with IBS?
Soluble fiber, such as that in oats or psyllium, can help IBS symptoms and constipation. Insoluble fiber, including wheat bran, may be less helpful for overall symptoms and can aggravate bloating in some patients. Increase fiber gradually because abrupt increases can worsen gas and discomfort. Selection should consider fiber type, bowel pattern, tolerance, and fluid intake rather than using a universal instruction to maximize all fiber.
Apply it
A patient with constipation-predominant IBS reports increased bloating after rapidly adding bran. Discuss a gradual soluble-fiber approach instead of abandoning every fiber-based option.
Common pitfall: Different fibers are not physiologically interchangeable. Symptoms after a sudden large increase may reflect dose and rate of introduction rather than proving that a carefully titrated alternative will fail.
NIDDK: Eating, Diet, and Nutrition for Irritable Bowel Syndrome
Nutrition4%
54.How is refeeding syndrome recognized and prevented?
Carbohydrate delivery after undernutrition raises insulin and shifts phosphate, potassium, and magnesium intracellularly. ASPEN grades decreases in one or more of these electrolytes within five days of calorie reintroduction: 10–20% mild, 20–30% moderate, and greater than 30% or qualifying organ dysfunction severe. Preventive adult measures include thiamine 100 mg before feeding or intravenous dextrose and frequent electrolyte monitoring in high-risk patients.
Apply it
A high-risk adult can begin approximately 10–20 kcal/kg during the first day with individualized advancement and electrolyte checks every 12 hours initially. Severe deficits require correction before initiation or escalation.
Common pitfall: Normal baseline serum values do not establish adequate stores. Count intravenous dextrose as carbohydrate delivery, and reduce calories when electrolyte decreases are precipitous or difficult to correct.
55.Why can vitamin B12 deficiency matter despite a reassuring blood count?
Vitamin B12 supports normal neurologic function as well as red-cell production. Deficiency can cause numbness, tingling, balance problems, and cognitive changes without the classic megaloblastic anemia pattern. A normal blood count therefore cannot be the sole gatekeeper when symptoms and risk factors are compatible. Identifying restrictive intake or impaired absorption helps determine the replacement strategy and whether continuing treatment is needed.
Apply it
An older patient with restricted intake develops numbness and gait difficulty without anemia. Include B12 deficiency in the assessment and investigate both dietary supply and absorption risks.
Common pitfall: Waiting for macrocytic anemia can delay recognition. Folate may improve hematologic findings without correcting B12-related neurologic injury, so a better blood count does not necessarily establish resolution.
Other Disorders7.5%
56.Which small-bowel obstruction findings require urgent surgery?
In suspected adhesive small-bowel obstruction, CT helps identify the transition, alternative causes, and complications. Peritonitis, strangulation, bowel ischemia, or a closed-loop obstruction requires urgent surgical assessment rather than a routine conservative trial. Uncomplicated adhesive obstruction can often receive bowel rest, decompression, intravenous fluids, and electrolyte correction with close reassessment. See the [WSES Bologna guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC6006983/).
Apply it
A patient with prior abdominal surgery has vomiting and CT evidence of a closed loop with reduced bowel enhancement. Obtain urgent surgical intervention while resuscitating.
Common pitfall: A history of adhesions does not make every obstruction safe to observe. Initial passage of stool or a single reassuring laboratory result does not exclude evolving ischemia.
Gastroenterology Certification Examination Expanded Blueprint
57.How is microscopic colitis diagnosed when the colon looks normal?
Microscopic colitis requires colonic biopsies because its defining inflammation can be invisible during colonoscopy. Consider it with chronic watery, nonbloody diarrhea, especially with urgency or nocturnal stools. Review whether tissue was actually obtained during a prior normal examination. Negative infection tests address different causes and do not replace histology. Collagenous colitis has a thickened subepithelial collagen layer; lymphocytic colitis lacks that defining band.
Apply it
A patient has persistent nocturnal watery diarrhea after negative infection studies and a normal unbiopsied colonoscopy. Obtain appropriate colonic tissue instead of repeating visual inspection alone.
Common pitfall: Several negative tests do not necessarily constitute a complete evaluation. Symptoms cannot reliably establish the histologic subtype, and medication associations do not independently prove causation.
NIDDK: Diagnosis of Microscopic Colitis · NIDDK: Definition and Facts of Microscopic Colitis · Symptoms & Causes of Microscopic Colitis - NIDDK
58.Which ischemic bowel presentations change imaging and endoscopy decisions?
Colon ischemia often causes sudden cramping pain followed by hematochezia. CT evaluates distribution and severity; early limited colonoscopy can confirm the diagnosis when safe. Isolated right-colon involvement, severe pain without bleeding, or atrial fibrillation raises concern for acute mesenteric ischemia and warrants multiphasic CT angiography. Peritonitis or evidence of irreversible ischemic damage precludes routine diagnostic colonoscopy and requires urgent surgical assessment. See the [ACG colon ischemia guideline](https://acgcdn.gi.org/wp-content/uploads/2018/04/ACG-Colon-Ischemia-Guideline-Summary.pdf).
Apply it
A patient with atrial fibrillation develops severe abdominal pain without rectal bleeding. Investigate mesenteric ischemia urgently rather than waiting for the classic bloody-diarrhea pattern.
Common pitfall: Absence of bleeding is not reassuring in a severe ischemic presentation. Pneumatosis with concerning clinical findings or portal venous gas raises concern for transmural injury.
Gastroenterology Certification Examination Expanded Blueprint
59.How does a diverticular abscess change management?
A diverticular abscess represents complicated diverticulitis. CT defines its size, location, and drainability. Small abscesses may respond to antibiotics; larger accessible collections commonly require image-guided drainage as well. Persistent sepsis, failure of drainage or medical treatment, or diffuse peritonitis requires surgical assessment. Fistula, stricture, and obstruction are additional complications that alter definitive planning. See the [ASCRS diverticular disease guidance](https://fascrs.org/Web/Web/Patients/Diseases-and-Conditions/A-Z/Diverticular-Disease-Expanded-Information.aspx).
Apply it
A stable patient has a 5 cm accessible diverticular abscess. Arrange antibiotics and drainage assessment rather than treating the episode as uncomplicated outpatient disease.
Common pitfall: A localized collection and free perforation with diffuse peritonitis require different strategies. Clinical deterioration overrides an initial plan for nonoperative treatment.
Gastroenterology Certification Examination Expanded Blueprint
60.When does C. difficile testing distinguish infection from colonization?
Test patients with unexplained new-onset diarrhea, typically at least three unformed stools in 24 hours, after considering alternative causes such as laxatives. NAAT detects toxigenic organisms and can be positive in colonization; toxin-containing multistep algorithms improve interpretation when stool-submission criteria are not tightly controlled. Diagnosis integrates symptoms with laboratory findings. Do not test asymptomatic patients to establish cure. See the [IDSA–SHEA diagnostic guideline](https://www.idsociety.org/practice-guideline/clostridium-difficile/).
Apply it
A patient develops new frequent watery stools after antibiotics without laxative exposure. Submit an appropriate diarrheal specimen and interpret the result in the clinical context.
Common pitfall: A positive molecular result without compatible illness is not sufficient evidence of active colitis. Persistent assay positivity after recovery does not establish treatment failure.
Gastroenterology Certification Examination Expanded Blueprint
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the full official outline to identify topics beyond this selective guide, including additional procedural, inflammatory, malignant, vascular, motility, and transplant-related disease.
- Prioritize liver disease according to its 20% weight, practising ascitic calculations, viral serology, fibrosis triage, recognition of acute failure, and transplant referral decisions.
- Rehearse procedural decisions involving bleeding control, antithrombotic management, sedation risk, perforation response, and patient comprehension.
- Match each test to its target and preparation: esophageal biopsies and treatment exposure, celiac antibody class, duodenal sampling, gastric emptying conditions, and colonic histology.
- Distinguish inflammatory activity from fixed obstruction, induction from maintenance, structural pancreatic disease from exocrine failure, and local tumor clearance from oncologic cure.
- Apply health-equity considerations through teach-back, language assistance, practical medication access, follow-up reliability, and nutritional adequacy.
A practical preparation plan
1. Map the complete certification scope
Read the January 2026 certification outline and expanded topic list. Allocate study time approximately by official domain weights and identify topics absent from this selective guide.
2. Identify the finding that changes management
For each concept, name the decisive finding, explain its mechanism, and state the next action. Examples include a visible ulcer vessel, an undrained abscess, qualifying ascitic neutrophils, and coagulopathy with acute encephalopathy.
3. Complete the clinical questions
Answer all 20 questions before reading explanations. Explain why the selected option fits and why each alternative fails in the stated setting.
4. Practise calculations and paired interpretation
Calculate SAAG and absolute ascitic neutrophils. Interpret HBsAg with core and surface antibodies, HCV antibody with RNA, and fibrosis scores with age and clinical stability.
5. Use spaced recall
Review the flashcards at spaced intervals. Answer with both the principle and a discriminating clinical cue; revisit the associated concept when recall does not translate into a decision.
6. Broaden preparation
Return to the full official outline for additional diseases, image interpretation, treatment selection, prognosis, and mechanisms. Include practical communication and access barriers when rehearsing clinical care.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM Gastroenterology Certification Policies
- Gastroenterology Certification Examination Blueprint — January 2026
- Gastroenterology Certification Examination Expanded Blueprint
- ABIM Expanded Blueprints
- ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding
- AHRQ: Use the Teach-Back Method
- ACG Eosinophilic Esophagitis Guideline Highlights — 2025
- ACG Guideline on Treatment of Helicobacter pylori: New Recommendations
- NIDDK: Eating, Diet, and Nutrition for Gastritis and Gastropathy
- NIH Office of Dietary Supplements: Vitamin B12
- NIDDK: Celiac Disease Tests
- The Updated 2025 ACG Guidelines to Manage Adult Ulcerative Colitis Patients
- ACG Clinical Guideline on Gastroparesis: Limited Evidence-Based Options
- NCI: Genetics of Colorectal Cancer (PDQ)
- ACR Liver Imaging Reporting and Data System
- ACR LI-RADS CT/MRI v2018 Core
- AASLD: HCC in Metabolic Dysfunction-Associated Steatotic Liver Disease
- AASLD: Why Timing Matters — Paracentesis on Admission for Cirrhosis with Ascites
- AASLD: Back to Basics — Decoding Hepatic Encephalopathy
- AASLD: Noninvasive Assessment of Patients with MASLD
- CDC: Clinical Testing and Diagnosis for Hepatitis B
- CDC: Clinical Screening and Diagnosis for Hepatitis C
- ACG Acute Pancreatitis Guideline Highlights — 2024
- NIDDK: Eating, Diet, and Nutrition for Irritable Bowel Syndrome
- NIDDK: Treatment for Irritable Bowel Syndrome
- ASPEN Consensus Recommendations for Refeeding Syndrome
- NIDDK: Diagnosis of Microscopic Colitis
- NIDDK: Definition and Facts of Microscopic Colitis
- ACG_-_Upper_GI_Bleed_2021.pdf
- ACG-Hpylori-Guidelines-Highlights-2024-FINAL.pdf
- Symptoms & Causes of Microscopic Colitis - NIDDK
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.